These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 36848033)

  • 21. An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.
    Vesin B; Lopez J; Noirat A; Authié P; Fert I; Le Chevalier F; Moncoq F; Nemirov K; Blanc C; Planchais C; Mouquet H; Guinet F; Hardy D; Vives FL; Gerke C; Anna F; Bourgine M; Majlessi L; Charneau P
    Mol Ther; 2022 Sep; 30(9):2984-2997. PubMed ID: 35484842
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety and Pharmacokinetic Assessments of a Novel Ivermectin Nasal Spray Formulation in a Pig Model.
    Errecalde J; Lifschitz A; Vecchioli G; Ceballos L; Errecalde F; Ballent M; Marín G; Daniele M; Turic E; Spitzer E; Toneguzzo F; Gold S; Krolewiecki A; Alvarez L; Lanusse C
    J Pharm Sci; 2021 Jun; 110(6):2501-2507. PubMed ID: 33493479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intranasal nanoemulsion adjuvanted S-2P vaccine demonstrates protection in hamsters and induces systemic, cell-mediated and mucosal immunity in mice.
    Ganesan S; Acosta H; Brigolin C; Orange K; Trabbic K; Chen C; Lien CE; Lin YJ; Lin MY; Chuang YS; Fattom A; Bitko V
    PLoS One; 2022; 17(11):e0272594. PubMed ID: 36322572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mucosal immunity: The missing link in comprehending SARS-CoV-2 infection and transmission.
    Russell MW; Mestecky J
    Front Immunol; 2022; 13():957107. PubMed ID: 36059541
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Bacterial Mucosal Immunotherapy MV130 Protects Against SARS-CoV-2 Infection and Improves COVID-19 Vaccines Immunogenicity.
    Del Fresno C; García-Arriaza J; Martínez-Cano S; Heras-Murillo I; Jarit-Cabanillas A; Amores-Iniesta J; Brandi P; Dunphy G; Suay-Corredera C; Pricolo MR; Vicente N; López-Perrote A; Cabezudo S; González-Corpas A; Llorca O; Alegre-Cebollada J; Garaigorta U; Gastaminza P; Esteban M; Sancho D
    Front Immunol; 2021; 12():748103. PubMed ID: 34867974
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Natural Derived Nasal Spray; A Proposed Approach for COVID-19 Disease Control.
    Hoseini-Tavassol Z; Ejtahed HS; Soroush AR; Sajjadpour Z; Hasani-Ranjbar S; Larijani B
    Infect Disord Drug Targets; 2021; 21(8):e160921191568. PubMed ID: 33602078
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Formulation, Device, and Clinical Factors Influencing the Targeted Delivery of COVID-19 Vaccines to the Lungs.
    Mossadeq S; Shah R; Shah V; Bagul M
    AAPS PharmSciTech; 2022 Nov; 24(1):2. PubMed ID: 36416999
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Respiratory mucosal delivery of next-generation COVID-19 vaccine provides robust protection against both ancestral and variant strains of SARS-CoV-2.
    Afkhami S; D'Agostino MR; Zhang A; Stacey HD; Marzok A; Kang A; Singh R; Bavananthasivam J; Ye G; Luo X; Wang F; Ang JC; Zganiacz A; Sankar U; Kazhdan N; Koenig JFE; Phelps A; Gameiro SF; Tang S; Jordana M; Wan Y; Mossman KL; Jeyanathan M; Gillgrass A; Medina MFC; Smaill F; Lichty BD; Miller MS; Xing Z
    Cell; 2022 Mar; 185(5):896-915.e19. PubMed ID: 35180381
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial mouthwashes (gargling) and nasal sprays to protect healthcare workers when undertaking aerosol-generating procedures (AGPs) on patients without suspected or confirmed COVID-19 infection.
    Burton MJ; Clarkson JE; Goulao B; Glenny AM; McBain AJ; Schilder AG; Webster KE; Worthington HV
    Cochrane Database Syst Rev; 2020 Sep; 9(9):CD013628. PubMed ID: 32936947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intranasal administration of a recombinant RBD vaccine induced protective immunity against SARS-CoV-2 in mouse.
    Du Y; Xu Y; Feng J; Hu L; Zhang Y; Zhang B; Guo W; Mai R; Chen L; Fang J; Zhang H; Peng T
    Vaccine; 2021 Apr; 39(16):2280-2287. PubMed ID: 33731271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Rapid Development and Early Success of Covid 19 Vaccines Have Raised Hopes for Accelerating the Cancer Treatment Mechanism.
    Amanpour S
    Arch Razi Inst; 2021 Mar; 76(1):1-6. PubMed ID: 33818952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A single intranasal administration of AdCOVID protects against SARS-CoV-2 infection in the upper and lower respiratory tracts.
    Schultz MD; Suschak JJ; Botta D; Silva-Sanchez A; King RG; Detchemendy TW; Meshram CD; Foote JB; Zhou F; Tipper JL; Zhang J; Harrod KS; Leal SM; Randall TD; Roberts MS; Georges B; Lund FE
    Hum Vaccin Immunother; 2022 Nov; 18(6):2127292. PubMed ID: 36194255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Do we need nasal vaccines against COVID 19 to suppress the transmission of infections?
    Brüssow H
    Microb Biotechnol; 2023 Jan; 16(1):3-14. PubMed ID: 36464938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in respiratory immunization: A focus on COVID-19 vaccines.
    He X; Chen X; Wang H; Du G; Sun X
    J Control Release; 2023 Mar; 355():655-674. PubMed ID: 36787821
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protective Effects of Astodrimer Sodium 1% Nasal Spray Formulation against SARS-CoV-2 Nasal Challenge in K18-hACE2 Mice.
    Paull JRA; Luscombe CA; Castellarnau A; Heery GP; Bobardt MD; Gallay PA
    Viruses; 2021 Aug; 13(8):. PubMed ID: 34452519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Virucidal activity of nasal sprays against severe acute respiratory syndrome coronavirus-2.
    Meister TL; Todt D; Brüggemann Y; Steinmann J; Banava S; Brill FHH; Steinmann J; Pfaender S; Steinmann E
    J Hosp Infect; 2022 Feb; 120():9-13. PubMed ID: 34752803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How nasal-spray vaccines could change the pandemic.
    Waltz E
    Nature; 2022 Sep; 609(7926):240-242. PubMed ID: 36068305
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.